|View printer-friendly version|
Xtant Medical Announces U.S. Commercial Launch of the Matriform® Si for Spinal Fusion Procedures
“We are excited to launch Matriform Si in the
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5d59db94-c877-4c1e-a75c-a31465e45437
Matriform® Si was developed to resemble the composition and porous structure of natural human bone. Comprised of 96% pure phase β-TCP granules and 4% bioglass, Matriform Si is designed to provide the ideal biomimetic scaffold for spinal fusion procedures. The flexible strip is designed to offer excellent handling and shape memory, ensuring direct contact with the surface of healthy bone.
Physicians and surgeons interested in learning more about the Matriform Si and other
The symbols ™ and ® denote trademarks and registered trademarks of
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “continue,” “future,” “will,” “may,” “continue,” similar expressions or the negative thereof, and the use of future dates. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risk involved in the introduction of new products; the effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to complete its pending debt restructuring, service its debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended
Investor Relations Contact
Source: Xtant Medical, Inc.